Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 49

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 49
---
S</div>

We currently intend to use the estimated net proceeds
from the sale of these securities for working capital and general corporate purposes, including to fund our product development efforts
and to fund our commercialization activities for our TAEUS technology. Accordingly, our management will have significant discretion and
flexibility in applying the net proceeds from the sale of these securities. Our plans to use the estimated net proceeds from the sale
of these securities may change, and if they do, we will update this information in a prospectus supplement.

<div align='center'>DESCRIPTION OF
SECURITIES WE MAY OFFER</div>

We may issue from time to time, in one or more
offerings, the following securities:

| ● | shares of common stock; |

| ● | shares of preferred stock; |

| ● | debt securities, which may include senior debt securities, subordinated debt securities and senior subordinated debt securities; |

| ● | warrants for the purchase of debt securities, preferred stock or common stock; and |

| ● | units consisting of two or more of the foregoing. |

Set forth below is a description of the common
stock and preferred stock that may be offered under this prospectus. We will set forth in the applicable prospectus supplement and/or
free writing prospectus a description of the debt securities and warrants that may be offered under this prospectus. The terms of the
offering of our common stock, preferred stock or any such other securities, the initial offering price and the net proceeds to us will
be contained in the prospectus supplement, and other offering material, relating to such offer.

We may sell the securities being offered pursuant
to this prospectus directly to purchasers, to or through underwriters, through dealers or agents, or through a combination of such methods.
The prospectus supplement with respect to the securities being offered will set forth the terms of the offering of those securities, including
the names of any such underwriters, dealers or agents, the purchase price, the net proceeds to us, any underwriting discounts and other
items constituting underwriters’ compensation, the initial public offering price, any discounts or concessions allowed or reallowed
or paid to dealers and any securities exchanges on which such securities may be listed.

<div align='center'>8

DESCRIPTION OF
COMMON STOCK WE MAY OFFER</div>

The following summary description of our common
stock is based on the provisions of our Fourth Amended and Restated Certificate of Incorporation, as amended, our Amended and Rest